原发性肝癌辨证分型标准尚未统一,长期以来未见论述原发性肝癌研究的中医诊疗方案及中医专家共识。本文结合相关文献和各位中医大家治疗原发性肝癌的研究工作,梳理原发性肝癌中医研究现状,概括古、今中医大家对该病的认识、思考及研究成...原发性肝癌辨证分型标准尚未统一,长期以来未见论述原发性肝癌研究的中医诊疗方案及中医专家共识。本文结合相关文献和各位中医大家治疗原发性肝癌的研究工作,梳理原发性肝癌中医研究现状,概括古、今中医大家对该病的认识、思考及研究成果,可供原发性肝癌中医、中西医临床和科研作一定的参考。The criteria for identification and typing of primary liver cancer have not been unified, and there has been no Chinese medicine diagnosis and treatment plan and Chinese medicine expert consensus on primary liver cancer research for a long time. This paper combines the relevant literature and the research work of Chinese medicine practitioners in the treatment of primary liver cancer to sort out the current status of Chinese medicine research on primary liver cancer, and summarize the knowledge, thoughts and research results of ancient and modern Chinese medicine practitioners on this disease, which can be used as a reference for Chinese medicine, Chinese and Western medicine, and clinical and scientific research on primary liver cancer.展开更多
肝硬化是各种慢性肝病的终末期,以感染乙型肝炎病毒(Hepatitis B virus)常见,据统计全球感染HBV人数达2.57亿,而腹水是肝硬化的常见并发症,预示着肝硬化进展为失代偿期,其临床预后不佳,3年内死亡率达50%。腹水的主要病因有肝硬化、恶性...肝硬化是各种慢性肝病的终末期,以感染乙型肝炎病毒(Hepatitis B virus)常见,据统计全球感染HBV人数达2.57亿,而腹水是肝硬化的常见并发症,预示着肝硬化进展为失代偿期,其临床预后不佳,3年内死亡率达50%。腹水的主要病因有肝硬化、恶性肿瘤及结核性腹膜炎,约占90%,其中肝硬化占60%~85%,恶性肿瘤占5%~15%,结核性腹膜炎占1%~5%,其他少见的病因包括心源性腹水、低蛋白血症腹水、肾脏病等。许多临床研究表明,中药复方治疗肝硬化腹水能有效抑制病情的进展、改善临床症状,具有疗效明确、不良反应少等优点。现将近年来中药复方治疗肝硬化腹水的临床研究综述如下。Liver cirrhosis is the end stage of various chronic liver diseases, mainly infected with hepatitis B virus (HBV). According to statistics, 257 million people are infected with HBV worldwide. Ascites is a common complication of liver cirrhosis, which indicates the progression of liver cirrhosis to decompensated stage, and its clinical prognosis is poor, with a mortality rate of 50% within 3 years. The main cause is liver cirrhosis, malignant ascites and tuberculous peritonitis, which accounts for about 90%, including cirrhosis accounted for 60%~85%, malignant tumor was 5%~15%, tuberculous peritonitis was 1%~5%, other rare causes include cardiac ascites, hypoalbuminemia ascites, kidney disease, etc. Many clinical studies have shown that Chinese traditional medicine compound treatment of cirrhosis ascites can effectively restrain the progress of the disease, improving clinical symptoms, and has the advantages of clear curative effect, less adverse reaction. This article reviews the clinical studies of traditional Chinese medicine compound in the treatment of liver cirrhosis ascites in recent years.展开更多
文摘原发性肝癌辨证分型标准尚未统一,长期以来未见论述原发性肝癌研究的中医诊疗方案及中医专家共识。本文结合相关文献和各位中医大家治疗原发性肝癌的研究工作,梳理原发性肝癌中医研究现状,概括古、今中医大家对该病的认识、思考及研究成果,可供原发性肝癌中医、中西医临床和科研作一定的参考。The criteria for identification and typing of primary liver cancer have not been unified, and there has been no Chinese medicine diagnosis and treatment plan and Chinese medicine expert consensus on primary liver cancer research for a long time. This paper combines the relevant literature and the research work of Chinese medicine practitioners in the treatment of primary liver cancer to sort out the current status of Chinese medicine research on primary liver cancer, and summarize the knowledge, thoughts and research results of ancient and modern Chinese medicine practitioners on this disease, which can be used as a reference for Chinese medicine, Chinese and Western medicine, and clinical and scientific research on primary liver cancer.
文摘肝硬化是各种慢性肝病的终末期,以感染乙型肝炎病毒(Hepatitis B virus)常见,据统计全球感染HBV人数达2.57亿,而腹水是肝硬化的常见并发症,预示着肝硬化进展为失代偿期,其临床预后不佳,3年内死亡率达50%。腹水的主要病因有肝硬化、恶性肿瘤及结核性腹膜炎,约占90%,其中肝硬化占60%~85%,恶性肿瘤占5%~15%,结核性腹膜炎占1%~5%,其他少见的病因包括心源性腹水、低蛋白血症腹水、肾脏病等。许多临床研究表明,中药复方治疗肝硬化腹水能有效抑制病情的进展、改善临床症状,具有疗效明确、不良反应少等优点。现将近年来中药复方治疗肝硬化腹水的临床研究综述如下。Liver cirrhosis is the end stage of various chronic liver diseases, mainly infected with hepatitis B virus (HBV). According to statistics, 257 million people are infected with HBV worldwide. Ascites is a common complication of liver cirrhosis, which indicates the progression of liver cirrhosis to decompensated stage, and its clinical prognosis is poor, with a mortality rate of 50% within 3 years. The main cause is liver cirrhosis, malignant ascites and tuberculous peritonitis, which accounts for about 90%, including cirrhosis accounted for 60%~85%, malignant tumor was 5%~15%, tuberculous peritonitis was 1%~5%, other rare causes include cardiac ascites, hypoalbuminemia ascites, kidney disease, etc. Many clinical studies have shown that Chinese traditional medicine compound treatment of cirrhosis ascites can effectively restrain the progress of the disease, improving clinical symptoms, and has the advantages of clear curative effect, less adverse reaction. This article reviews the clinical studies of traditional Chinese medicine compound in the treatment of liver cirrhosis ascites in recent years.
